Last updated: September 4, 2026
Acyclovir/hydrocortisone is a mature, niche prescription dermatology product sold primarily as Xerese, a topical cream containing acyclovir 5% and hydrocortisone 1%. Its commercial opportunity is limited by low-cost acyclovir generics, over-the-counter docosanol, short treatment duration, and the narrow indication of recurrent herpes labialis. The combination retains clinical differentiation because it pairs antiviral therapy with a low-potency corticosteroid, but its financial profile is more consistent with a specialty legacy product than a growth pharmaceutical asset.
What is acyclovir and hydrocortisone cream?
Acyclovir/hydrocortisone cream is a fixed-dose topical combination for the early treatment of recurrent herpes labialis, commonly called cold sores or fever blisters. The reference product, Xerese, contains:
| Product attribute |
Detail |
| Brand |
Xerese |
| Active ingredients |
Acyclovir 5%; hydrocortisone 1% |
| Dosage form |
Topical cream |
| Route |
Cutaneous |
| FDA application |
NDA 022436 |
| Indication |
Recurrent herpes labialis |
| Treatment schedule |
Five applications daily for five days |
| Regulatory category |
Prescription drug |
| Primary commercial rationale |
Antiviral activity combined with reduction of local inflammation |
Acyclovir inhibits herpes simplex virus DNA polymerase after intracellular phosphorylation. Hydrocortisone reduces inflammatory symptoms. The combination does not eliminate latent herpes simplex virus infection or prevent future recurrences.
The FDA approved Xerese in 2009 based on clinical studies evaluating recurrent herpes labialis. The product was developed to improve lesion healing and symptom outcomes compared with vehicle treatment containing hydrocortisone alone or placebo-controlled formulations (U.S. Food and Drug Administration [FDA], 2009).
How large is the acyclovir and hydrocortisone market?
The combination market is small relative to the broader acyclovir market. Public companies generally do not disclose Xerese revenue separately, and market research reports frequently aggregate the product with broader topical antivirals or herpes treatments. The most important commercial distinction is between the total acyclovir market and the fixed-dose acyclovir/hydrocortisone segment.
| Market segment |
Commercial profile |
| Oral acyclovir |
Large, mature generic market |
| Topical acyclovir |
Low-price generic market with limited differentiation |
| Acyclovir/hydrocortisone cream |
Niche prescription combination |
| Valacyclovir |
Large oral generic market with stronger convenience |
| Docosanol 10% cream |
OTC competitor for cold sores |
| Penciclovir cream |
Prescription topical competitor |
| Famciclovir |
Oral prescription generic competitor |
The addressable population is defined by patients who seek treatment for recurrent cold sores and receive prescription topical therapy. Many patients self-treat with docosanol, petroleum products, analgesics, or no medication. Physicians may choose oral valacyclovir or acyclovir for patients with frequent, severe, or highly symptomatic outbreaks.
The fixed-dose product therefore competes for a narrow treatment window. Patients must begin therapy at the earliest sign of recurrence, which limits demand among patients who present after vesicle formation.
What drives revenue for acyclovir and hydrocortisone?
Revenue is driven by prescription volume, payer coverage, reimbursement, pharmacy substitution, and the price gap between the brand and generic product.
Prescription dynamics
Acyclovir/hydrocortisone has a recognizable clinical proposition: it combines two established agents in one cream. The value proposition is strongest for patients with inflammatory cold-sore symptoms, including redness, swelling, and discomfort.
Demand is weakened by:
- The short five-day treatment course.
- The episodic nature of herpes labialis.
- Low diagnosis and treatment intensity.
- The availability of oral generic antivirals.
- Consumer familiarity with OTC docosanol.
- Limited willingness to pay for a branded topical product.
- Potential substitution by compounded or generic formulations.
The product’s revenue base is likely concentrated in dermatology, primary care, urgent care, and selected telemedicine channels. Direct-to-consumer awareness has less economic impact than for chronic dermatology drugs because recurrent cold sores are often self-managed.
Pricing and reimbursement
Topical prescription products face significant formulary pressure when the active ingredients are old and inexpensive. A brand product can preserve pricing only if it has one or more of the following:
- Favorable insurance coverage.
- A copay program.
- Pharmacy-level substitution controls.
- Demonstrated clinical convenience.
- A distribution strategy focused on cash-pay or telehealth patients.
Acyclovir/hydrocortisone lacks the recurring monthly revenue profile of chronic dermatology drugs. Each prescription is tied to an outbreak, and many patients do not refill consistently.
What patents protect acyclovir and hydrocortisone cream?
The original acyclovir and hydrocortisone combination was developed after the expiration of acyclovir’s core antiviral patents. The commercial protection therefore depended on formulation, combination, regulatory, and brand-related rights rather than on a new-molecule patent.
| Protection category |
Position |
| Acyclovir composition-of-matter patent |
Expired |
| Hydrocortisone composition-of-matter patent |
Expired |
| Fixed-dose combination protection |
Potentially formulation or method based |
| FDA marketing exclusivity |
Expired for the 2009 approval |
| Trademark protection |
Potentially available for Xerese |
| Manufacturing know-how |
Relevant, but usually difficult to enforce independently |
| Orange Book value |
Limited compared with new chemical entities |
The original FDA approval received the standard period of new-drug exclusivity applicable to the approved combination. That exclusivity expired years ago. Any remaining patent value would depend on the status and scope of formulation or method-of-use patents listed for NDA 022436, as well as the enforceability of those patents against an ANDA applicant.
The most defensible commercial conclusion is that the product does not have durable composition-of-matter protection. Its remaining barriers are practical: formulation development, regulatory filing cost, manufacturing validation, quality control, commercial access, and prescriber behavior.
What is the Orange Book status of acyclovir and hydrocortisone?
The relevant reference listed drug is Xerese, associated with FDA NDA 022436. The FDA Orange Book determines whether a listed patent or regulatory exclusivity period can support a Paragraph IV certification and a 30-month litigation stay.
For a generic applicant, the principal regulatory routes are:
- ANDA submission referencing the approved combination.
- Paragraph III certification if a listed patent remains valid.
- Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed.
- Suit by the NDA holder within 45 days of notice, if applicable.
- A potential 30-month stay under the Hatch-Waxman framework.
Because the active ingredients are old and the formulation is straightforward, an ANDA applicant would normally focus on bioequivalence, product quality, inactive ingredients, microbiological controls, and patent certification. The product is not a biologic, so biosimilar regulation does not apply.
When does acyclovir and hydrocortisone lose exclusivity?
Acyclovir/hydrocortisone lost its principal regulatory exclusivity years ago. Xerese was approved in 2009, and the associated new-drug exclusivity period did not create a long-term barrier to generic entry.
The exclusivity timeline is:
| Event |
Timing |
| Xerese FDA approval |
2009 |
| Initial regulatory exclusivity |
Expired |
| Core acyclovir patents |
Expired before the combination’s approval |
| Generic entry risk |
Present after regulatory and patent barriers |
| Current commercial protection |
Brand, formulation, distribution, and prescriber preference |
Patent expiration depends on the specific patent family and any applicable patent-term adjustment or extension. The business value of the product should not be underwritten on the assumption that the original acyclovir patents provide protection.
Which companies are challenging or competing with the product?
Competition comes from both branded and generic products. The main alternatives are not limited to direct fixed-dose combinations.
Direct and near-direct competitors
- Generic acyclovir cream.
- Penciclovir 1% cream, marketed as Denavir historically.
- Docosanol 10% cream, marketed as Abreva in the United States.
- Oral valacyclovir.
- Oral acyclovir.
- Oral famciclovir.
- Supportive OTC products.
Generic manufacturers can compete through lower acquisition cost and pharmacy substitution. OTC manufacturers compete through consumer accessibility. Oral antiviral manufacturers compete through dosing convenience and potentially broader clinical use.
Acyclovir/hydrocortisone can be favored when a prescriber wants topical treatment and visible inflammatory symptoms are present. Oral therapy is generally more attractive when patients have frequent lesions, multiple sites, severe symptoms, or a need for rapid episodic treatment.
How strong is the patent estate for acyclovir and hydrocortisone?
The patent estate is weak to moderate from an investment perspective.
Strengths
- The fixed-dose product is more differentiated than plain acyclovir cream.
- A specific formulation can create development and manufacturing hurdles.
- A brand may retain prescriber recognition after patent expiry.
- Combination products can be harder to replicate than single-ingredient products if inactive ingredients or process controls are complex.
Weaknesses
- Both active ingredients are long-established.
- The therapeutic indication is narrow.
- Regulatory exclusivity has expired.
- Clinical differentiation is incremental rather than transformative.
- Generic substitution can compress net price.
- Patent claims directed broadly to acyclovir, hydrocortisone, or herpes treatment are vulnerable to prior-art challenges.
The strongest residual protection would normally come from narrow formulation claims, process claims, or specific method-of-use claims. Those claims must be assessed against the product’s current Orange Book listing, patent expiration dates, prosecution history, and prior-art record.
What generic launch risks exist?
Generic launch risk is material. A generic competitor would not need to reproduce a new chemical entity, establish a novel mechanism, or run a large efficacy program. The primary requirements would be pharmaceutical equivalence, bioequivalence or equivalent performance, manufacturing compliance, and an acceptable patent certification.
A generic launch could produce several effects:
| Launch effect |
Expected commercial consequence |
| Pharmacy substitution |
Rapid erosion of branded volume |
| Lower generic price |
Net-price compression |
| Payer preference |
Reduced formulary access for the brand |
| Multiple ANDA entrants |
Further price decline |
| Limited supply competition |
Potential temporary price stability |
| Brand copay support |
Partial retention of cash-pay patients |
The market may support only a small number of profitable competitors because demand is episodic and the treatment course is short. That constraint can slow entry relative to larger generic categories, but it does not create durable brand protection.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate. Acyclovir is poorly water-soluble, and topical delivery requires a stable cream system that provides acceptable skin feel, uniform drug distribution, preservative performance, and product stability. The addition of hydrocortisone creates further requirements for content uniformity and stability testing.
Key technical issues include:
- Particle size and suspension control.
- Uniform distribution of acyclovir and hydrocortisone.
- Cream rheology and spreadability.
- Stability under temperature variation.
- Microbial limits and preservative effectiveness.
- Container-closure compatibility.
- Scale-up reproducibility.
- Control of degradation products.
These issues can delay generic development, but they generally do not create the same barrier as complex injectables, inhaled products, transdermal systems, or biologics. Manufacturing know-how can protect execution quality without generating strong exclusionary rights.
What is the financial trajectory for acyclovir and hydrocortisone?
The financial trajectory is mature to declining for the branded product and stable to expanding in low-cost generic volume.
Brand trajectory
The likely brand pattern is:
- Initial post-launch growth from prescription adoption.
- Plateau after clinical awareness develops.
- Pressure from generic acyclovir, oral antivirals, and OTC products.
- Revenue erosion following generic entry or payer exclusion.
- Residual cash flow from loyal prescribers, specialty distribution, or cash-pay channels.
The product is unlikely to generate meaningful growth from population expansion alone. Herpes labialis is common, but the treated prescription market is constrained by self-care and episodic use. The commercial strategy would need to rely on price discipline, payer access, channel management, or acquisition synergies.
Generic trajectory
Generic manufacturers could achieve attractive margins if they enter before market crowding. Once multiple suppliers are approved, prices would likely decline. The market’s small size can preserve some rational pricing if there are few competitors, but the underlying ingredients do not justify a premium.
Revenue exposure
The revenue exposure is concentrated in the product itself because there is limited platform leverage. The product does not establish a large franchise around a chronic disease, nor does it create a significant follow-on pipeline. Its value is therefore best assessed through:
- Current net sales.
- Gross margin after rebates and distribution fees.
- Remaining patent life.
- Number of approved or pending ANDAs.
- Payer coverage.
- Prescription volume trend.
- Brand-to-generic substitution rate.
- Customer acquisition cost.
Public filings from diversified pharmaceutical companies may not identify Xerese revenue separately. A standalone valuation should therefore use product-level prescription and net-sales data rather than corporate revenue multiples.
How does acyclovir/hydrocortisone compare with competing cold-sore treatments?
| Product |
Main advantage |
Main weakness |
Commercial position |
| Acyclovir/hydrocortisone |
Combination antiviral and anti-inflammatory treatment |
Prescription-only and niche |
Differentiated legacy product |
| Generic acyclovir cream |
Low price |
Less differentiated |
Generic pressure |
| Docosanol |
OTC access |
Modest efficacy and consumer self-treatment |
Strong accessibility |
| Penciclovir cream |
Established topical prescription option |
Higher cost and narrow use |
Specialty alternative |
| Valacyclovir |
Oral convenience and broader use |
Systemic exposure and prescription requirement |
Strong generic competitor |
| Famciclovir |
Oral episodic therapy |
Generic competition |
Alternative for selected patients |
Acyclovir/hydrocortisone is most defensible where topical administration and inflammation control matter. It is less competitive when patients prioritize convenience, low price, or early oral treatment.
What litigation and settlement risks affect the product?
There is no major biologic-style patent litigation framework because the product is a conventional topical combination. Litigation risk would arise primarily from an ANDA Paragraph IV filing, a patent-infringement action by the NDA holder, or disputes over formulation equivalence and labeling.
A settlement could include:
- An agreed generic launch date.
- A license to a generic manufacturer.
- Authorized-generic supply.
- No-challenge provisions subject to antitrust limits.
- Restrictions on marketing or distribution.
The economic effect of litigation depends on whether the patent claims cover the commercial product broadly enough to delay several generic entrants. Narrow claims would provide limited value even if successfully enforced.
Key Takeaways
- Acyclovir/hydrocortisone is a mature prescription combination centered on Xerese.
- The product contains acyclovir 5% and hydrocortisone 1% for recurrent herpes labialis.
- Regulatory exclusivity from the 2009 FDA approval has expired.
- Core patents covering acyclovir and hydrocortisone do not provide current product protection.
- Remaining patent value depends on formulation and method-of-use claims, if any remain enforceable and listed.
- Generic entry risk is material because the active ingredients are old and the treatment is technically manageable.
- Revenue is constrained by OTC docosanol, oral generic antivirals, short treatment duration, and self-treatment.
- The branded product is a cash-flow and channel-management asset, not a high-growth pharmaceutical franchise.
- Generic economics depend on the number of entrants, payer substitution, and manufacturing complexity.
- Biosimilar risk does not apply because acyclovir/hydrocortisone is a conventional small-molecule topical drug.
FAQs
Is acyclovir and hydrocortisone the same as Xerese?
Yes. Xerese is the principal branded product containing acyclovir 5% and hydrocortisone 1% cream for recurrent herpes labialis.
Is acyclovir/hydrocortisone available over the counter?
The combination is marketed as a prescription product in the United States. Docosanol 10% cream is the principal OTC antiviral alternative.
Can generic manufacturers make acyclovir/hydrocortisone cream?
Yes. Generic entry is legally and technically possible through the ANDA pathway, subject to FDA requirements and any remaining listed patents.
Does acyclovir/hydrocortisone have biosimilar competition?
No. Biosimilars apply to biologic products. Acyclovir/hydrocortisone is a conventional small-molecule topical combination.
Is acyclovir/hydrocortisone a strong pharmaceutical investment?
It is more suitable as a mature specialty or generic opportunity than as a high-growth branded investment. The main value drivers are manufacturing cost, payer access, remaining patent rights, generic timing, and current prescription volume.
References
-
U.S. Food and Drug Administration. (2009). Xerese (acyclovir and hydrocortisone) cream, 5%/1%: Prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Centers for Disease Control and Prevention. (2024). About herpes simplex virus. U.S. Department of Health and Human Services.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.
